School of Medicine
Showing 201-220 of 587 Results
-
Alexis Reeves
Postdoctoral Scholar, Epidemiology
BioAlexis is a Propel postdoctoral scholar in the Department of Epidemiology and Population Health in the School of Medicine with Dr. Michelle Odden’s lab. Her research is broadly focused on the causes and consequences of racial disparities in accelerated aging. She is particularly interested in the interplay of structural and interpersonal racism, and the psychobiological mechanisms in which they produce early health declines in minoritized populations. Her work to date has focused on the health of Black women as they enter into life-stages, such as the midlife menopausal transition, where cardio-metabolic risk is high. Alexis also has a strong interest in causal inference, and applies causal inference theory and methods to these areas of research to mitigate and quantify bias.
-
Matthew F. Reeves
Adjunct Clinical Associate Professor, Obstetrics & Gynecology
BioDr. Matthew Reeves is the Executive Director and founder of the DuPont Clinic, a center providing patient-centered abortion care in all trimesters. With the team at the DuPont Clinic, Dr. Reeves has worked to re-envision the patient experience, create a new patient flow without a waiting room, develop new shortened protocols for later abortion, improve nurse-administered moderate sedation techniques, and introduce new and redesigned gynecologic instruments. Dr. Reeves also serves on the board of directors of DKT International, a social marketing organization that provided over 44 million couple-years of contraception in over 25 countries and is now the sole distributor for Ipas aspirators and Sino-Implant II. Previously, he was Medical Director of the National Abortion Federation where he worked to improve the quality of abortion care across North and South America. From 2010-2014, Dr. Reeves was the Chief Medical Officer of WomanCare Global where his work focused on expanding use of manual uterine aspiration and introducing mifepristone and levonorgestrel implants to new markets. Throughout his career, Dr. Reeves has worked on clinical research, primarily in the areas of post-abortal intrauterine contraception and improvements in abortion service delivery. In addition to this appointment at Stanford, he currently has an appointment as an Adjunct Associate Professor at the Johns Hopkins Bloomberg School of Public Health. Dr. Reeves attended Harvard Medical School and completed residency in obstetrics & gynecology at the University of California, San Francisco (UCSF). He then completed the fellowship in Clinical Ultrasound at UCSF followed by the Fellowship in Family Planning at the University of Pittsburgh.
-
Shobha Regmi
Postdoctoral Scholar, Radiology
BioResearch interest: Mesenchymal stem cell transplantation, Stem cell biology, Islet transplantation, Biomaterials, Drug delivery
-
Donald Regula, MD
Professor (Teaching) of Pathology and, by courtesy, of Orthopaedic Surgery
BioDr. Regula was the course director for the required medical student course, Science of Medicine, and previously the course director of the required pathology course (1993-2020)
He was the Director of the Stanford Autopsy Service (1995-2021)
He is the faculty co-lead for the EPIC Beaker-AP implementation project. -
David Rehkopf
Associate Professor of Epidemiology and Population Health, of Medicine (Primary Care and Population Health) and, by courtesy, of Sociology, of Pediatrics and of Health Policy
BioI am a social epidemiologist and serve as an Associate Professor in the Department of Epidemiology and Population Health and in the Department of Medicine in the Division of Primary Care and Population Health. I joined the faculty at Stanford School of Medicine in 2011.
I am Director of the Stanford Center for Population Health Sciences. In this position, I am committed to making high-value data resources available to researchers across disciplines in order to better enable them to answer their most pressing clinical and population health questions.
My own research is focused on understanding the health implications of the myriad decisions that are made by corporations and governments every day - decisions that profoundly shape the social and economic worlds in which we live and work. While these changes are often invisible to us on a daily basis, these seemingly minor actions and decisions form structural nudges that can create better or worse health at a population level. My work demonstrates the health implications of corporate and governmental decisions that can give the public and policy makers evidence to support new strategies for promoting health and well-being. In all of his work, I have a focus on the implications of these exposures for health inequalities.
Since often policy and programmatic changes can take decades to influence health, my work also includes more basic research in understanding biological signals that may act as early warning signs of systemic disease, in particular accelerated aging. I examine how social and economic policy changes influence a range of early markers of disease and aging, with a particular recent focus on DNA methylation. I am supported by several grants from the National Institute on Aging and the National Institute on Minority Health and Health Disparities to develop new more sensitive ways to understand the health implications of social and economic policy changes. -
James H Reich
Adjunct Professor, Psych/General Psychiatry and Psychology (Adult)
BioI attended U.C. Berkeley for my B.S. degree, the University of Colorado for my MD and U.C. Davis for my psychiatric residency and did a fellowship in Psychiatric Epidemiology at Yale. I have been faculty at the University of Iowa, Harvard and Brown. I have published over a hundred papers in peer reviewed journals, mostly in the areas of anxiety and personality. I also founded a medical society, the Association for Research in Personality Disorders (ARPD).
Currently I am in private practice in San Francisco and teach at Stanford and UCSF. My treatment approaches for psychotherapy include CBT and mindfulness. I also do psychopharmacology which I have taught UCSF for many years.
I am also a board certified forensic psychiatrist in private practice focusing largely on civil cases. -
Daryn Reicherter
Clinical Professor, Psychiatry and Behavioral Sciences
BioDr. Reicherter the director of the Human Rights in Trauma Mental Health Laboratory.
He has expertise in the area of cross-cultural trauma psychiatry, having spent more than a decade dedicated to providing a combination of administrative and clinical services in trauma mental health locally and internationally. He is on the List of Experts for the Extraordinary Chambers in the Courts of Cambodia and for the United Nations’ International Criminal Court. He is on the Fulbright Specialists Roster for his work in international trauma mental health. He is a Senior Fellow at the Center for Innovations in Global Health at Stanford University. He has created and cultivated new clinical rotations for residency education and medical school education in the community clinics that he operates. And he has created new opportunities for resident, medical student, and undergraduate education in Global Mental Health.
He has also been involved in the creation of clinical mental health programs for underserved populations in the San Francisco Bay Area. He is the Faculty Adviser for the Stanford’s Free Clinic Mental Health Program.
After receiving degrees in Psychobiology and Philosophy from the University of California at Santa Cruz, Dr. Reicherter completed his doctorate in medicine at New York Medical College. He completed internship and residency and served as Chief Resident at Stanford University Hospitals and Clinics. -
Richard J. Reimer, MD
Associate Professor of Neurology (Adult Neurology)
Current Research and Scholarly InterestsReimer Lab interests
A primary interest of our lab is to understand how nerve cells make and recycle neurotransmitters, the small molecules that they use to communicate with each other. In better defining these processes we hope to achieve our long-term goal of identifying novel sites for treatment of diseases such as epilepsy and Parkinson Disease. In our studies on neurotransmitter metabolism we have focused our efforts on transporters, a functional class of proteins that move neurotransmitters and other small molecules across membranes in cells. Transporters have many characteristics that make them excellent pharmacological targets, and not surprisingly some of the most effective treatments for neuropsychiatric disorders are directed at transporters. We are specifically focusing on two groups of transporters vesicular neurotransmitter transporters that package neurotransmitters into vesicles for release, and glutamine transporters that shuttle glutamine, a precursor for two major neurotransmitters glutamate and GABA, to neurons from glia, the supporting cells that surround them. We are pursuing these goals through molecular and biochemical studies, and, in collaboration with the Huguenard and Prince labs, through physiological and biosensor based imaging studies to better understand how pharmacological targeting of these molecules will influence neurological disorders.
A second interest of our lab is to define mechanism underlying the pathology of lysosomal storage disorders. Lysosomes are membrane bound acidic intracellular organelles filled with hydrolytic enzymes that normally function as recycling centers within cells by breaking down damaged cellular macromolecules. Several degenerative diseases designated as lysosomal storage disorders (LSDs) are associated with the accumulation of material within lysosomes. Tay-Sachs disease, Neimann-Pick disease and Gaucher disease are some of the more common LSDs. For reasons that remain incompletely understood, these diseases often affect the nervous system out of proportion to other organs. As a model for LSDs we are studying the lysosomal free sialic acid storage disorders. These diseases are the result of a defect in transport of sialic acid across lysosomal membranes and are associated with mutations in the gene encoding the sialic acid transporter sialin. We are using molecular, genetic and biochemical approaches to better define the normal function of sialin and to determine how loss of sialin function leads to neurodevelopmental defects and neurodegeneration associated with the lysosomal free sialic acid storage disorders.
